Khiron Life Sciences Corp. (TSXV:KHRN), a Canadian cannabis stock, powered up after receiving authorization to manufacture THC magistral preparations in Colombia
Regulatory approval in Colombia lifted a Canadian cannabis stock Friday. Here’s some small stocks making big moves on Friday, March 20, 2020 (as of 11:30 am EST):
Khiron Life Sciences Corp. (TSXV:KHRN), a Canadian cannabis stock with operations in Latin America, jumped 16% to $0.465 on Friday after announcing that it is now fully authorized to manufacture high- and low-THC magistral preparations in Colombia and anticipates fulfilling its first prescriptions of full-spectrum, high CBD formulations within days.
As well, shares of K-Bro Linen Inc. (TSX:KBL) slipped 13% to $28.04 as the operator of laundry and linen processing facilities said its 2019 revenue rose 5.4% to a record $252.4 million, while EBITDA for the year increased to $47.6 million from $29.6 million in 2018. The Company, however, added that it expects the COVID-19 pandemic will have a “significant adverse impact” on its operations and financial results in 2020, particularly in the second quarter.
Auxly Cannabis Group Inc. (TSXV:XLY), meanwhile, reported that Alan Cooke has joined Auxly as Vice President, Domestic and International Supply Chain and Operations. Mr. Cooke is the former manager of cultivation operations at Canopy Growth and has spent over 20 years in senior management roles in supply-chain and operations, with companies such as British American Tobacco and Canada Bread. Auxly Cannabis stock moved up 17% to $0.27 following the announcement.
Disclosure: Neither the author nor his family own shares in any of the companies mentioned above.
To read our full disclosure, please click on the button below:
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.
Khiron Life Sciences Corp. (TSXV:KHRN), a Canadian cannabis stock with operations in Latin America, jumped 16% to $0.465 on Friday after announcing that it is now fully authorized to manufacture high- and low-THC magistral preparations in Colombia and anticipates fulfilling its first prescriptions of full-spectrum, high CBD formulations within days.
, on Friday.){kind=link}